Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
Adult
Antiviral Agents
/ therapeutic use
Coinfection
/ diagnostic imaging
Elasticity Imaging Techniques
Female
France
HIV Infections
/ diagnostic imaging
Hepatitis C, Chronic
/ diagnostic imaging
Humans
Liver
/ diagnostic imaging
Male
Middle Aged
Mortality
Proportional Hazards Models
Prospective Studies
Risk Factors
Sustained Virologic Response
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
10
2018
accepted:
10
01
2019
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
29
10
2019
Statut:
epublish
Résumé
The association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study. HIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included. Cox proportional hazards models with delayed entry were performed to determine factors associated with all-cause mortality. LSM and SVR were considered as time dependent covariates. 1,062 patients were included from 2005 to 2015 (69.8% men, median age 45.7 years (IQR 42.4-49.1)). 21.7% had baseline LSM >12.5 kPa. Median follow-up was 4.9 years (IQR 3.2-6.1). 727 (68.5%) were ever treated for HCV: 189 of them (26.0%) achieved SVR. 76 deaths were observed (26 liver-related, 10 HIV-related, 29 non-liver-non-HIV-related, 11 of unknown cause). At the age of 50, the mortality rate was 4.5% for patients with LSM ≤12.5 kPa and 10.8% for patients with LSM >12.5 kPa. LSM >12.5 kPa (adjusted Hazard Ratio [aHR] = 3.35 [2.06; 5.45], p<0.0001), history of HCV treatment (aHR = 0.53 [0.32; 0.90], p = 0.01) and smoking (past (aHR = 5.69 [1.56; 20.78]) and current (3.22 [0.93; 11.09]) versus never, p = 0.01) were associated with all-cause mortality independently of SVR, age, sex, alcohol use and metabolic disorders. Any LSM >12.5 kPa was strongly associated with all-cause mortality independently of SVR and other important covariates. Our results suggest that close follow-up of these patients should remain a priority even after achieving SVR.
Sections du résumé
BACKGROUND
The association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study.
METHODS
HIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included. Cox proportional hazards models with delayed entry were performed to determine factors associated with all-cause mortality. LSM and SVR were considered as time dependent covariates.
RESULTS
1,062 patients were included from 2005 to 2015 (69.8% men, median age 45.7 years (IQR 42.4-49.1)). 21.7% had baseline LSM >12.5 kPa. Median follow-up was 4.9 years (IQR 3.2-6.1). 727 (68.5%) were ever treated for HCV: 189 of them (26.0%) achieved SVR. 76 deaths were observed (26 liver-related, 10 HIV-related, 29 non-liver-non-HIV-related, 11 of unknown cause). At the age of 50, the mortality rate was 4.5% for patients with LSM ≤12.5 kPa and 10.8% for patients with LSM >12.5 kPa. LSM >12.5 kPa (adjusted Hazard Ratio [aHR] = 3.35 [2.06; 5.45], p<0.0001), history of HCV treatment (aHR = 0.53 [0.32; 0.90], p = 0.01) and smoking (past (aHR = 5.69 [1.56; 20.78]) and current (3.22 [0.93; 11.09]) versus never, p = 0.01) were associated with all-cause mortality independently of SVR, age, sex, alcohol use and metabolic disorders.
CONCLUSION
Any LSM >12.5 kPa was strongly associated with all-cause mortality independently of SVR and other important covariates. Our results suggest that close follow-up of these patients should remain a priority even after achieving SVR.
Identifiants
pubmed: 30682180
doi: 10.1371/journal.pone.0211286
pii: PONE-D-18-29412
pmc: PMC6347250
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211286Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2003 Jul 5;362(9377):22-9
pubmed: 12853195
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
JAMA. 2012 Jul 25;308(4):370-8
pubmed: 22820790
Open Forum Infect Dis. 2015 Jul 09;2(3):ofv109
pubmed: 26284259
AIDS. 2014 Aug 24;28(13):1957-65
pubmed: 25259703
Hepatology. 2009 Aug;50(2):407-13
pubmed: 19575364
AIDS. 2007 Oct 18;21(16):2209-16
pubmed: 18090048
J Hepatol. 2015 Sep;63(3):573-80
pubmed: 25937433
JAMA. 2015 Mar 24-31;313(12):1232-9
pubmed: 25706232
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
Lancet. 2015 Mar 21;385(9973):1098-106
pubmed: 25659285
HIV Med. 2014 Apr;15(4):203-12
pubmed: 24245909
N Engl J Med. 2009 Apr 30;360(18):1815-26
pubmed: 19339714
PLoS One. 2015 Sep 29;10(9):e0138838
pubmed: 26418061
AIDS. 2016 Mar 13;30(5):723-9
pubmed: 26595542
Clin Infect Dis. 2013 Jun;56(11):1646-53
pubmed: 23429381
AIDS. 2015 Sep 10;29(14):1821-30
pubmed: 26372388
BMC Infect Dis. 2010 Oct 22;10:303
pubmed: 20969743
Lancet. 2000 Nov 25;356(9244):1800-5
pubmed: 11117912
J Hepatol. 2017 Jul;67(1):23-31
pubmed: 28235612
Lancet. 2003 Nov 22;362(9397):1708-13
pubmed: 14643119
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
AIDS Res Hum Retroviruses. 2012 Oct;28(10):1235-43
pubmed: 22443303
Hepatology. 2009 Oct;50(4):1056-63
pubmed: 19670415
Clin Infect Dis. 2012 Sep;55(5):728-36
pubmed: 22610932
Dig Dis Sci. 2015 Nov;60(11):3473-81
pubmed: 26112991
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):175-9
pubmed: 16394849
PLoS One. 2016 Mar 02;11(3):e0150512
pubmed: 26933963
AIDS. 2015 Jun 19;29(10):1205-15
pubmed: 25870984
Clin Infect Dis. 2001 Aug 15;33(4):562-9
pubmed: 11462196
Hepatology. 2009 Aug;50(2):387-92
pubmed: 19591128
Biostatistics. 2009 Jul;10(3):535-49
pubmed: 19369642
Clin Infect Dis. 2016 Sep 15;63(6):821-829
pubmed: 27307505
Clin Infect Dis. 2016 Sep 15;63(6):763-770
pubmed: 27317796
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):280-7
pubmed: 25157646
AIDS. 2014 May 15;28(8):1181-91
pubmed: 24901259